News | October 16, 2023
ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Lokavant provides clinical trial intelligence
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
30 beneficiaries avail of services per minute
Dr. Jitendra Singh inaugurates 300 LPM capacity Oxygen Plant, Day Care Chemotherapy Unit affiliated to Tata Memorial Hospital & Maternal ICU at GMC Kathua
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Public private partnership (PPP) with integrated strategy essential to achieve ‘TB Mukt Bharat’ by 2025
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Subscribe To Our Newsletter & Stay Updated
